Cargando…
Peptide-based immunotherapy of experimental autoimmune encephalomyelitis without anaphylaxis
Administration of peptide antigens in tolerogenic form holds promise as a specific treatment for autoimmune and allergic disorders. However, experiments in rodent autoimmune models have highlighted the risk of anaphylaxis in response to systemic peptide application once the aberrant immune response...
Autores principales: | Leech, Melanie D, Chung, Chen-Yen, Culshaw, Abigail, Anderton, Stephen M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
WILEY-VCH Verlag
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699421/ https://www.ncbi.nlm.nih.gov/pubmed/18000952 http://dx.doi.org/10.1002/eji.200737148 |
Ejemplares similares
-
TnP Peptide Suppresses Experimental Autoimmune Encephalomyelitis (EAE) in a Preclinical Mouse Model
por: Lima, Carla, et al.
Publicado: (2022) -
TLR-4 ligation of dendritic cells is sufficient to drive pathogenic T cell function in experimental autoimmune encephalomyelitis
por: Mellanby, Richard J, et al.
Publicado: (2012) -
PD‐1 expression is upregulated on adapted T cells in experimental autoimmune encephalomyelitis but is not required to maintain a hyporesponsive state
por: Mair, Iris, et al.
Publicado: (2018) -
Clozapine Regulates Microglia and Is Effective in Chronic Experimental Autoimmune Encephalomyelitis
por: Ceylan, Ulaş, et al.
Publicado: (2021) -
Parthenolide Suppresses T Helper 17 and Alleviates Experimental Autoimmune Encephalomyelitis
por: Zhang, Zhihui, et al.
Publicado: (2022)